{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:44:52Z","timestamp":1792719892980,"version":"4.5.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>We aimed to determine the impact of fibroblast activation protein inhibitor (FAPI)\u2013directed molecular imaging on staging and therapeutic management in patients affected with digestive system tumors when compared with guideline-compatible imaging (GCI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Thirty-two patients with tumors of the digestive system were included: colon adenocarcinoma, 2\/32 (6.3%); hepatocellular carcinoma (HCC), 6\/32 (18.8%); pancreatic duct adenocarcinoma (PDAC), 6\/32 (18.8%), and gastroenteropancreatic neuroendocrine neoplasms, 18\/32 (56.3%). All patients underwent GCI and <jats:sup>68<\/jats:sup>Ga-FAPI-04 PET\/CT within median 4 days. Staging outcomes and subsequent treatment decisions were compared between GCI and <jats:sup>68<\/jats:sup>Ga-FAPI-04 PET\/CT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Compared with GCI, <jats:sup>68<\/jats:sup>Ga-FAPI-04 PET\/CT led to staging changes in 15\/32 patients (46.9%). Among those, downstaging was recorded in 3\/15 cases (20.0%) and upstaging in the remaining 12\/15 patients (HCC, 4\/12 [33.3%]; PDAC, 4\/12 [33.3%]; neuroendocrine neoplasms, 3\/12 [25%]; colon adenocarcinoma, 1\/12 [8.3%]). Therapeutic management was impacted in 8\/32 patients (25.0%), including 4 instances of major and 4 instances of minor therapeutic changes. The highest proportion of treatment modifications was observed in patients diagnosed with PDAC and HCC in 6\/8 (75%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In patients affected with digestive system tumors, <jats:sup>68<\/jats:sup>Ga-FAPI-04 PET\/CT resulted in staging changes in more than 46% and therapeutic modifications in 25% of the cases, in particular in patients with HCC and PDAC. In clinical routine, such findings may favor a more widespread adoption of FAP-directed imaging in those tumor types.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004480","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T15:00:29Z","timestamp":1668092429000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":43,"title":["Impact of 68Ga-FAPI-04 PET\/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors"],"prefix":"10.1097","volume":"48","author":[{"given":"Aleksander","family":"Kosmala","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Schl\u00f6telburg","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lindner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Michalski","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schirbel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Weich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","year":"2021","journal-title":"Cancer"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.2014.60.2847","article-title":"Use of imaging for GI cancers","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"S560","DOI":"10.1016\/j.jacr.2017.08.050","article-title":"ACR Appropriateness Criteria\u00ae staging of pancreatic ductal adenocarcinoma","volume":"14","year":"2017","journal-title":"J Am Coll Radiol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.jacr.2022.02.012","article-title":"ACR Appropriateness Criteria\u00ae staging of colorectal cancer: 2021 update","volume":"19","year":"2022","journal-title":"J Am Coll Radiol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/000313480306900208","article-title":"The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma","volume":"69","year":"2003","journal-title":"Am Surg"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"17804","DOI":"10.3748\/wjg.v20.i47.17804","article-title":"Cancer-associated fibroblasts in digestive tumors","volume":"20","year":"2014","journal-title":"World J Gastroenterol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1148\/radiol.2020203275","article-title":"Comparison of (68)Ga-FAPI and (18)F-FDG uptake in gastric, duodenal, and colorectal cancers","volume":"298","year":"2021","journal-title":"Radiology"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1007\/s00259-022-05847-0","article-title":"Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","article-title":"Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET\/CT in cancer patients","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/RLU.0000000000004189","article-title":"Interobserver agreement rates on fibroblast activation protein inhibitor-directed molecular imaging and therapy","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","year":"2022","journal-title":"J Hepatol"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1245\/s10434-017-5810-x","article-title":"Validation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with pancreatic adenocarcinoma: a Surveillance, Epidemiology and End Results (SEER) analysis","volume":"24","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.4143\/crt.2019.023","article-title":"Validation of the 8th AJCC Cancer Staging System for pancreas neuroendocrine tumors using Korean Nationwide Surgery Database","volume":"51","year":"2019","journal-title":"Cancer Res Treat"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/030089161009600532","article-title":"The ENETS guidelines: the new TNM classification system","volume":"96","year":"2010","journal-title":"Tumori"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","year":"2020","journal-title":"Histopathology"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1245\/s10434-017-6025-x","article-title":"8th edition of the AJCC Cancer Staging Manual: pancreas and hepatobiliary cancers","volume":"25","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.119.237016","article-title":"The role of (68)Ga-FAPI PET\/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2967\/jnumed.120.253062","article-title":"Impact of (68)Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s00259-021-05576-w","article-title":"Positron emission tomography and computed tomography with [(68)Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00259-021-05494-x","article-title":"Head-to-head comparison of [(68)Ga]Ga-FAPI-04 and [(18)F]-FDG PET\/CT in evaluating the extent of disease in gastric adenocarcinoma","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"693640","DOI":"10.3389\/fonc.2021.693640","article-title":"(68)Ga-FAPI-04 versus (18)F-FDG PET\/CT in the detection of hepatocellular carcinoma","volume":"11","year":"2021","journal-title":"Front Oncologia"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.sla.0000217629.94941.cf","article-title":"Epidemiology and management of liver metastases from colorectal cancer","volume":"244","year":"2006","journal-title":"Ann Surg"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11864-022-00968-y","article-title":"An update on the management of mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN)","volume":"23","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11864-022-00967-z","article-title":"New PET radiotracers for the imaging of neuroendocrine neoplasms","volume":"23","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-021-05488-9","article-title":"FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1055\/a-1521-8604","article-title":"Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET\/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours","volume":"60","year":"2021","journal-title":"Nuklearmedizin"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/RLU.0000000000003490","article-title":"68Ga-FAPI PET\/CT versus 68Ga-DOTATATE PET\/CT in the evaluation of a patient with neuroendocrine tumor","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/RLU.0000000000003763","article-title":"Comparison of 18F-FDG, 68Ga-FAPI, and 68Ga-DOTATATE PET\/CT in a patient with pancreatic neuroendocrine tumor","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1007\/s00259-021-05247-w","article-title":"The superiority of [(68)Ga]Ga-FAPI-04 over [(18)F]-FDG in a case of neuroendocrine tumour with hepatic metastasis","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/RLU.0000000000003811","article-title":"68Ga-DOTA-FAPI-04 PET\/CT in neuroendocrine carcinoma of the liver with elevated AFP level: comparison with 18F-FDG PET\/CT","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2967\/jnumed.119.241232","article-title":"FAP: the next billion dollar nuclear theranostics target?","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib39-20250621","article-title":"Mixed neuroendocrine non-neuroendocrine neoplasms: a systematic review of a controversial and underestimated diagnosis","volume":"9","year":"2020","journal-title":"J Clin Med"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/cncr.28760","article-title":"Therapeutic strategies for neuroendocrine liver metastases","volume":"121","year":"2015","journal-title":"Cancer"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:02:20Z","timestamp":1750536140000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004480","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}